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Abstract This retrospective study was designed to evaluate the safety and efficacy of a bronchoprotective sputum
inductionprotocolinmoderate to severe chronic obstructive pulmonarydisease (COPD).Forty-two adultswith COPD
(FEV1 = 51.7+3.2% predicted (mean+SEM)) underwent sputuminductionusinga protocoldesigned tominimize hyper-
tonic saline-induced bronchoconstriction.Hypertonic (3%) saline was used for subjects with FEV1 50%, and normal
(0.9%) saline was used for subjects with FEV1o50%.Primary outcomeswere change in peak flow,FEV1and oxygen sa-
turation.Mean decline in peak flow during sputum induction was 13.2+2.1%. FEV1 fell by 11.4+2.3%, an absolute fall of
0.14+0.03 l.Oxygen saturation did not change. A fall in peak flow of 20% reliably predicted a fall in FEV1 of 20%.
Thirty-five of 42 subjects (83.3%) produced an acceptable sputum sample. Sputum eosinophil and neutrophil percen-
tages were 2.8+0.9 and 73.0+3.0%, respectively, and were not correlated with changes in peak flow, FEV1or oxygen
saturation. A protocol for sputum inductionwhich restricts the use of hypertonic saline based on lung function is both
safe and effective in subjectswithmoderate to severe COPD.r2002 Elsevier Science Ltd.Allrights reserved.
doi:10.1053/rmed.2002.1342, available online at http://www.idealibrary.comon
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Sputum induction is a safe (1,2) andwidely-utilizednonin-
vasive method for obtaining lower airway specimens in
asthma clinical research (3), but it has been used less fre-
quently in the study of chronic obstructive pulmonary
disease (COPD). Sputum induction e¡ectively samples
the lower airway and allows evaluation of markers of in-
£ammation (4). It is particularly useful as a noninvasive
technique when expiratory air£ow limitation precludes
airway sampling via bronchoscopy. Sputum analysis may
also be useful clinically; sputum eosinophilia has been
shown to predict clinical response to corticosteroids in
patients with COPD (5,6).
In subjectswithCOPD, potential risks associatedwith
sputum induction include worsened expiratory air£ow
limitation and oxygen desaturation.Hypertonic (3%) sal-
ine has been shown to induce greater bronchoconstric-
tion during sputum induction in COPD when compared
with normal (0.9%) saline (7). Prior studies (4,8^10) have
reported the results of spirometry and/or oximetry per-Received13 February 2002, accepted in revised form 27 February 2002.
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398 -1780; E-mail: martinr@njc.orgformed during and after sputum induction with varying
results, but fewof these studies (11) have evaluated these
parameters as primary outcomes following sputum in-
duction.
We conducted a retrospective study to evaluate the
safety and e⁄cacy of sputum induction in subjects with
moderate to severeCOPD.Wehypothesized that a stan-
dardized sputum induction protocol which requires fre-
quent lung function monitoring and limits the use of
hypertonic saline to subjects with FEV1 50% would
have minimal deleterious e¡ects on lung function and
oxygen saturationwhile yielding acceptable sputum spe-
cimens at a rate similar to that previously reported (12).
METHODS
Study design and subject characteristics
The cohort for this retrospective data analysis was con-
stituted from two separate and ongoing prospective
cohort studies: one of ambient air pollution e¡ects on
COPD, the other a prospective cross-over drug trial in
COPD.All researchwas approvedby theNational Jewish
Medical and Research Center Institutional Review
Board. Sputum induction was performed prior to any
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jects with COPD (all subjects from the two trials with
complete data available) were evaluated.
In addition to a10 pack/year smokinghistory and age
440 years, all subjects were required to satisfy at least
one of the following diagnostic criteria for COPD (13) as
inclusion criteria: (1) chronic symptoms of cough or spu-
tumproduction, (2) FEV1o70%ofpredicted, or (3) FEV1/
FVCo 80%. Subjects could be current smokers.Use of
inhaledor systemic corticosteroidswithin 6weeks of en-
rollment was a cause for exclusion, as was the presence
of other clinically signi¢cant lung disease, upper respira-
tory tract infection and/or antibiotic usewithin 6weeks,
unstable lung disease (de¢ned as42 acute care hospita-
lizations for COPD in the last year), signi¢cant nonpul-
monary medical illness and inability to adhere to the
study protocol.
Sputum induction
A standardized protocol for sputum induction was uti-
lized (Fig.1).Prior to sputuminduction, baseline spirome-FIG. 1. Sputum induction protocol. SI = sputum induction, PEFR =
albuterol andwere able to be dischargedwithout additional therapy
tion.Inductionterminated if FEV1declined =20% compared to post-atry (Eagle 2 Spirometer, Collins Medical, Braintree, MA,
U.S.A.) and peak expiratory £ow rate measurements
(Airwatch, LifeChart.com, Mountain View, CA, USA or
Mini-Wright, Clement Clarke, Columbus, OH, U.S.A.)
were obtained before and after albuterol, 360mcg.
Baseline post-albuterol FEV1 determined the saline con-
centration utilized for inhalation: if a subject had a base-
line FEV150% of predicted, hypertonic salinewas used.
If the baseline FEV1waso50%, normal salinewas used.
Subjects inhaled nebulized (Ultra-Neb 99, DeVilbiss
Health Care, Inc., Somerset, PA,U.S.A.) saline solution,
for 2minutes expectorated saliva into a discard contain-
er, coughed sputum into a sterile collection container
and then performed a peak £ow maneuver. If the peak
£owrate had not fallen by20% from the post-albuterol
baseline, sputum inductionwas continuedwith interrup-
tions at 2minutes intervals for expectoration and peak
£owmeasurement, up to a total time of12min.
If peak £owdid fall by20%,FEV1wasmeasured. If the
FEV1 had not fallen by 20% from the post-albuterol
baseline, then sputum induction was continued, with in-
terruptions every 2minutes for expectoration and FEV1peak expiratory £ow rate, * all subjects responded to 180mcg
, w peak £owor FEV1measured every 2minutes during continua-
lbuterolbaseline.
TABLE 1. COPD disease severity [13] among study sub-
jects.
COPD stage Numberof subjects
0Fat risk 1
IFmild 3
IIAFmoderate 13
IIBFmoderate 21
IIIFsevere 4
TABLE 2. Subjectcharacteristics
Gender (F/M) 14/28
Age (years) 65.7+1.5*
Currentcigarette use N = 6
DLCo (% predicted) 48.2+2.6*
Baseline peak expiratory £ow rate (l/
min)
273+17.1*
Post-albuterol FEV1 (l) 1.52+0.12*
Post-albuterol FEV1 (% predicted) 51.7+3.2*
Bronchodilator reversibility (l) 0.15+0.03*
Bronchodilator reversibility (%) 16.7+3.1*
Post-albuterol FEV1/FVC (%) 45.3+2.1*
Baseline pulse oximetry (%) 92.9+0.5*
Supplemental oxygenuse N = 11
(range1^4 l/min)
Sputuminductionwith 0.9% saline N = 27
*mean+SEM.
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total time of 12minutes. If the FEV1 fell by 20% at any
point, then sputum inductionwas terminated.
Subjects receiving supplemental oxygen used oxygen
at their usual £owrate. All subjectshad continuous pulse
oximetry (Propaq, Protocol Systems, Inc., Beaverton,
OR, U.S.A.) performed. Oxygen desaturation of 5%
served as a criterion for termination of sputum induc-
tion. All subjects had FEV1measured at the end of spu-
tum induction. Albuterol (180^360mcg) was
administered if the post-sputum induction FEV1was not
90% of the pre-sputum induction baseline FEV1. All
subjects had an FEV1of 90% of the pre-sputum induction
baseline FEV1prior to discharge.
Sputumprocessing and analysis
Induced sputumwasweighed and a volume of dithiothrei-
tol (Sputolysin10%,Caldon Biotech,Carlsbad,CA,U.S.A.)
equal to theweight of the sputum (1ml Sputolysin10% for
each gram sputum)was then added. Aftermixing, the so-
lution was incubated in a 371C water bath shaker for
15minutes. Additional mixing with a pipette was per-
formed every 5minutes during incubation to ensure ade-
quate homogenization.One milliliter of the mixture was
withdrawn, smeared on a glass slide and stained (Hema 3
stain, Biochemical Sciences, Inc., Swedesborough, NJ,
U.S.A.) for absolute anddi¡erential cell count. Di¡erential
cell counts were expressed as a percent of nonsquamous
cells. A sputum samplewas considered adequate if (1) spu-
tum induction was longer than 4minutes in duration and
(2) sputum containedo80% squamous cells (14).
Outcomemeasures
The primary outcomes were changes in peak £ow, FEV1
and pulse oximetry. Secondary outcome measures in-
cluded sputum volume and sputum cell count and di¡er-
ential.
Statistical analyses
Statistical analyses were performed using STATA (Inter-
cooled, version 7.0, STATACorporation,College Station,
TX, U.S.A.). Paired data (pre- and post-sputum induc-
tion) were analyzed using theWilcoxon signed-rank test
(15). All the correlations were analyzed using Spearman’s
rankcorrelation coe⁄cient (16). All statistical testswere
performed at the 95% signi¢cance level.
RESULTS
Subjects
Using consensus criteria (13), themajority of subjects (38
of 42, 90.4%) had moderate or severe COPD (Table 1).
Additional subject characteristics are listed inTable 2.Changes in peak £ow with sputuminduction
All subjects had peak £ow measurements performed.
Peak £ow prior to sputum induction was 273+17 l
minutes (mean+SEM). Following sputum induction,
peak £ow was 239+17.The absolute fall in peak £ow as
a result of sputum induction was 34+6 l/minutes
(Po0.0001), a percent fall of 13.1+2.1%.12 subjects had a
fall in peak £ow of20%, which prompted lung function
monitoring with FEV1 for the remainder of the proce-
dure (as described above). Fall in peak £ow was not sig-
ni¢cantly correlated with the percent saline used for
sputum induction.
Changes in FEV1with sputum induction
A subset of subjects contributed FEV1data to the analy-
sis. In14 of the 30 subjects who did not experience a sig-
ni¢cant fall in peak £ow, FEV1 at the end of sputum
induction was recorded as a binary variable, scored
‘‘yes’’ or ‘‘no’’ based on whether the post-sputum induc-
tion FEV1was 90% of the pre-sputum induction FEV1.
Sixteen of 30 subjects had post-sputum induction FEV1
recorded as a continuous variable. These 16 subjects,
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£owof20%, provided 28 complete sets of FEV1data for
analysis.
In these 28 subjects, baseline (post-albuterol, pre-spu-
tum induction) FEV1 was 1.53+0.16 l (52.8+4.3 % pre-
dicted). The pre-albuterol, post-sputum induction FEV1
was1.4+0.16 l.This corresponded to a change in FEV1of
0.14+0.03 l (11.4+2.3%, P=0.0001). Sputum induction
was terminated in 8 subjects due to a decline in FEV1 of
20% (absolute change 0.27+0.04 l) from baseline. Two
of the 8 subjects had a decline in FEV1 20% without a
concomitant fall in FEV1of200ml.Therewas no signi¢-
cant correlation between standardmeasures of bronch-
odilator reversibility (17) performed before sputum
induction and fall in FEV1 (P40.05). Fall in FEV1was not
signi¢cantly correlated (P40.05) with the percent saline
used for sputum induction.
Change in peak £owas a predictor of change
in FEV1
Percent changes in peak £ow were positively correlated
with percent changes in FEV1 (Spearman’s r = 0.71,
Po0.0001, Figure 2). A fall in peak £ow20% frombase-
line performed well as a diagnostic test for a fall in FEV1
of 20%, with a sensitivity of 100% and a speci¢city of
75%.This corresponded to a positive predictive value of
67%, a negative predictive value of 100%, and a positive
likelihood ratio of 4.
Changes in oxygenationwith sputum
induction
Thirty eight subjects had complete continuous pulse oxi-
metrydata available for analysis.11of 42 subjects (26%) of
subjects received supplemental oxygen.Oxygen satura-
tion did not change during sputum induction; mean oxy-
gen saturation was 93+1% before and after sputum
induction.FIG. 2. The fallinpeakexpiratory £owrate and FEV1with spu-
tuminduction are positivelycorrelated.Sputumproduction and cellularity
Thirty-¢ve of 42 subjects (83.3%) produced an accepta-
ble sputum sample.The use of normal saline was not as-
sociatedwith signi¢cantly increasedriskof an inadequate
sputum specimen (risk ratio = 1.2, 95% con¢dence inter-
val 0.91^1.59). Sputum weight was 3.9+0.5 g. Of the 35
subjects with acceptable sputum samples, 30 sputum dif-
ferential cell counts were available for analysis. Sputum
eosinophils were 2.8+0.9% and sputum neutrophils
were 73.0+3.0%. Sputum eosinophils and neutrophils
were not signi¢cantly correlated with baseline FEV1
(P40.05), degree of bronchodilator reversibility
(P40.05), change in lung function during sputum induc-
tion (P40.05), change in oxygenation during sputum in-
duction (P40.05), or sputumvolume (P40.05).
Adverse events
No adverse events occurred during sputum induction.
All the subjects were able to be discharged from the la-
boratory with an FEV190% of the post-albuterol base-
line. In19 subjects (45%), albuterol 360mcg was required
after sputum induction to achieve this discharge criter-
ion.No subject reported an exacerbation of COPD as a
result of sputum induction.
DISCUSSION
The protocol utilized in this study di¡ers from pre-
viously-published protocols (8^12,18) for sputum induc-
tion in COPD. Several features of this protocol were
designed to enhance subject safety. First, the use of hy-
pertonic saline is restricted to subjects with baseline
FEV1 50% of predicted. Subjects with FEV1o50% of
predicted were induced with 0.9% saline in an attempt
to minimize airway irritation and bronchoconstriction
associated with the use of 3% saline.Using normal saline
tominimize theriskof bronchoconstriction iswarranted
given the recent observation of Taube and colleagues (7)
that the use of 3% saline is associated with greater
bronchoconstriction and greater levels of sputum hista-
mine than is the use of 0.9% saline (7). Second, measure-
ments of lung function were performed every 2minutes
and constant pulse oximetry was performed to facilitate
earlydetection of signi¢cantchanges in lung function and
gas exchange. Third, treatment with albuterol was pro-
vided after sputum induction to insure that thedischarge
FEV1was within10% of the pre-induction baseline level.
Based on our ¢ndings, monitoring lung function dur-
ing sputum inductionwith peak £ow alone is safe and re-
£ective of changes in FEV1. Changes in peak £ow
correlated positively and signi¢cantly with changes in
FEV1and all cases of a decline FEV1of20% frombaseline
were detectedusing a 20% fall as the threshold change in
peak £ow rate. Finally, introducing an option for the use
486 RESPIRATORYMEDICINEof normal saline into the sputum induction protocol does
not appear to reduce the likelihood of an acceptable spu-
tum sample; overall, this protocol yielded adequate spu-
tum samples 83% of the time, a success rate similar to
that reportedwith other protocols (12).
We were unable to demonstrate signi¢cant correla-
tions between the degree of bronchoconstriction during
sputum induction and baseline FEV1, degree of broncho-
dilator reversibility, saline concentration or sputum in-
£ammatory cell type. This indicates that traditional
indicators of disease severity and airway in£ammation
are not good predictors of bronchoconstriction when
this sputum induction protocol is utilized. It may also in-
dicate that this protocol is bronchoprotective, reducing
the risk of bronchoconstriction to those subjects with
more severe airways disease.
The results of this study support the use of this stan-
dardized sputum induction protocol as a safe and e¡ec-
tivenoninvasivemethod of sampling the lower airways in
subjects with moderate to severe chronic obstructive
pulmonary disease.
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